Researchers at Sanford Research have created an animal model to study choroid plexus carcinoma, a pediatric brain tumor. The study identified a new genetic pathway and targeted the Sonic Hedgehog protein as a potential treatment.
Two studies from Massachusetts General Hospital suggest that targeting both VEGF and Ang-2 pathways can normalize tumor blood vessels and shift immune cells towards an anti-tumor state. This approach has shown promise in slowing glioblastoma growth and improving survival rates.
Castro aims to develop novel immunotherapies for brain cancer using cutting-edge technology, including genetically engineered mouse models and gene transfer technologies. Her research focuses on understanding the tumor immune-microenvironment and its response to therapeutics.
A small clinical study using the anticancer drug bevacizumab has restored hearing in a handful of people with neurofibromatosis type 2, who previously suffered from progressive hearing loss. The treatment showed promise in reducing tumor size without affecting nerve function.
Innovative chemotherapy delivery methods for brain tumors are explored, including intra-arterial delivery, osmotic disruption, and implantable polymers. These strategies aim to enhance therapeutic agent distribution in the CNS, raising interest in the oncology community.
Researchers found PGK1 plays a key role in coordinating cellular processes for cancer metabolism and brain tumor formation. The enzyme promotes energy production through the Warburg effect, leading to rapid cancer growth.
Researchers at KU Leuven have developed a novel cell-based immunotherapy that combines chemotherapy, inducing specific type of cell death in brain cancer cells. This approach stimulates the immune system to attack and activate dendritic cells, resulting in a drastically increased survival rate of mice with brain tumors.
Researchers developed a novel brain tumor model in mice with DNA damage-repair problems, which can help test new treatments for children's brain cancer. The model shows that treating tumors with DNA-damaging drugs can shrink them more effectively and improve survival.
Researchers at St. Jude Children's Research Hospital and the German Cancer Research Center have identified four new subtypes of a rare childhood brain tumor using molecular techniques. This discovery is expected to improve diagnosis accuracy and treatment options for these hard-to-treat cancers.
Researchers analyzed myeloid lineage immune cells in glioblastoma patients, revealing non-polarized cell state and potential therapeutic strategy. The study suggests stimulating these cells to adopt an anti-tumor identity may be effective.
Researchers have found that laser ablation creates a temporary opening in the blood-brain barrier, allowing chemotherapy drugs to pass into the brain. This breakthrough raises hopes for longer treatment options and improved patient outcomes.
Using laser probe, neurosurgeons deliver chemotherapy drugs to patients with glioblastoma after opening the blood-brain barrier. The technology allows for longer treatment windows and potentially limits harmful effects of chemotherapy.
A new report from the American Brain Tumor Association reveals that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39. The study, which analyzed data from 2008-2012, also found a shift towards high-grade tumors with increasing age.
Lund University scientists discovered that malignant tumors consume more sugar than surrounding tissue, making sugar a promising non-synthetic contrast agent. The study's results suggest the potential to reduce medical care costs by replacing metal-based agents with sugar-based alternatives.
A multi-institutional report presents the first known experience of robotic nephrectomy for inferior vena cava tumor thrombus, achieving favorable outcomes and reproducibility in surgeons with adequate robotic experience. Complications were relatively minor, but some patient deaths occurred despite minimally invasive approach
Researchers created a combined MRI and ultramicroscopy toolkit to study vessel growth in glioma models, providing better understanding of underlying mechanisms and potential novel targets for future drug development. The technique helped assess the effects of existing anti-vascular endothelial growth factor treatments on tumour growth.
Researchers at St. Jude Children's Research Hospital found that adult survivors of childhood brain tumors exhibit significant cognitive deficits in intelligence, educational achievement, and employment. The study also showed that hydrocephalus is associated with poor cognitive function, even decades after treatment.
The UPMC-developed GlioSeq test provides rapid and accurate profiling of genetic abnormalities in brain tumors, guiding treatment planning. This next-generation sequencing test identifies previously known alterations as well as new molecular markers, enabling personalized management of patients.
Researchers identified a pivotal role of the Miz1 protein in determining tumor identity and its interaction with Myc proteins driving group 3 medulloblastoma. The study suggests targeting the Miz1-Myc complex may suppress the spread of group 3 tumors.
Researchers at Salk Institute identify nuclear factor kB as a key player in glioblastoma multiforme proliferation. Targeting this protein with NBD peptide or Timp1 gene slows tumor growth and increases mouse survival time, offering potential new treatment avenues.
Researchers discovered a novel pathway to cancer that involves the misfolding of the genome and IDH mutations. This disruption allows a potent growth factor gene to be activated by an always-on gene switch, leading to cancer growth.
Vestibular schwannomas cause hearing loss by secreting toxic molecules like TNFa, which damages the inner ear. The study provides a new mechanism for sensorineural hearing loss in these tumors.
A woman with treatment-resistant depression was found to have a brain tumor after symptoms persisted for six months despite antidepressant and anti-anxiety medication. The tumor, located in her left frontal lobe, was later treated successfully with emergency surgery, resulting in the disappearance of depressive symptoms.
A new cell culture technique called VOGIM allows the formation of tumor blood vessels and their interaction with immune cells to be observed in real-time. This enables the study of tumor growth, cell death, and the influence of medications on these developments without live animal testing.
Researchers at Penn State College of Medicine have developed a new nanotechnology approach using 'smart fat cells' that can pass the blood-brain barrier to detect early-stage brain tumors. This breakthrough could transform gliomas from a death sentence into a treatable condition, enabling patients to receive timely treatment.
Researchers found that combining TTFields with chemotherapy significantly improved progression-free and overall survival for patients with glioblastoma. The study, published in JAMA, suggests a potential new treatment approach for this devastating brain tumor.
Researchers at the University of Cambridge have developed a non-invasive blood test that can diagnose some types of malignant childhood tumour with high accuracy. The test looks for specific genetic code patterns in blood and cerebrospinal fluid samples, allowing for early diagnosis and monitoring without exposure to radiation.
Researchers have found that tumors driven by IDH1 mutations are vulnerable to depletion of metabolite NAD+, which supports the development of new treatments. Inhibiting NAD+ levels can induce the death of IDH1-mutant tumor cells and inhibit tumor growth in animal models.
Researchers reveal brain cancer's highly organized structure, with glioma cells forming streams, swirls, and spheres to protect and spread tumor growth. These structures are not related to specific cancer mutations and can be targeted for treatment.
University of Oregon scientists have identified a molecular change in aging stem cells that stops them from making tumors. The discovery, detailed in the journal Current Biology, focuses on the larval stage of fruit fly development and reveals that a protein called Eyeless plays a crucial role in regulating Notch signaling.
A recent study published in Cancer Cell found that a key signaling pathway present in most organisms actually suppresses the formation of specific types of brain tumor, including gliomas. This discovery has significant implications for glioma treatment and diagnosis.
Researchers develop nanoparticles that can carry therapeutics across the brain blood barrier, offering new hope for treating glioblastoma multiforme. The 3HM nanocarriers show promising attributes for treating brain cancers.
A new study by Siyuan Zhang and colleagues reveals that the microenvironment of tumor cells has a significant impact on cancer metastasis. The study suggests that the 'seed and soil' model, where tumors adapt to new tissues, can be used to prevent metastasis.
Treatment with anti-angiogenesis drugs improves radiation treatment of nervous system tumors in animal models, reducing tumor size and nerve damage. Anti-VEGF treatment enhances nerve regeneration and decreases muscle atrophy.
Researchers propose using cerebrospinal fluid as a liquid biopsy for early diagnosis, prognosis, therapeutic management, and tracking of brain cancer. Concentrations of circulating central nervous system tumor DNA are higher in CSF than in plasma.
A study published in Environmental Health found that short-lived environmental factors, such as common infections and atmospheric pollution, may be involved in the development of neuroblastic tumours in children. The research identified temporal clustering of cases in northern England over a 43-year period.
Researchers at Massachusetts General Hospital have reported the first successful use of a targeted therapy drug to treat a patient with a debilitating, recurrent brain tumor. Treatment with BRAF inhibitor dabrafinib led to rapid shrinkage of the tumor, and the patient remains symptom-free over a year after treatment.
A new study reveals that chemotherapy-induced hearing loss in pediatric brain tumor survivors can lead to significant neurocognitive deficits, including intelligence, executive function, and verbal reasoning skills. Children who received radiation therapy and developed hearing loss are at particularly high-risk for these deficits.
Researchers have identified a protein inside blood vessels at the invasive edge of brain tumours, enabling more accurate mapping and potentially improving treatment outcomes. The new imaging technique could lead to better surgery and radiotherapy for patients with brain tumours.
Researchers are testing a stimulated Raman scattering microscope to image brain tissue in real-time, allowing surgeons to see the difference between tumor tissue and normal brain. The technology has the potential to resolve a long-standing issue in cancer surgery by providing faster and more effective methods to assess tumor removal.
Case Western Reserve University researcher Efstathios Karathanasis has received a $2.82 million grant to develop a treatment that eradicates glioblastoma multiforme with one safe dose. The treatment uses chain-like nanoparticles carrying chemotherapy medicine and inhibitors to target brain tumor cells.
Inserm researchers have developed a noninvasive brain imaging method using MRI that provides the same information as physical palpation, allowing for early diagnosis of brain tumors or Alzheimer's disease. The technique uses noise correlation to detect natural shear waves in the brain, enabling building images of the brain's elasticity.
Researchers have identified a virus-drug combination that shows improved effectiveness against brain tumor cells, specifically glioblastoma. The combination of the myxoma virus and certain existing drugs, such as axitinib, reduces tumor-initiating cell viability by 20% or more.
Researchers found that adult survivors of pediatric posterior fossa brain tumors performed significantly lower on standardized clinical tests of working memory, and had increased blood-oxygen level dependent activation in prefrontal regions.
A new meta-analysis found that being overweight or obese increases the risk of meningioma by 21% and 54%, respectively. Conversely, high physical activity was associated with a decreased risk of meningioma.
Researchers found diminished interaction among cytokines in people who later developed tumors five years before diagnosis. This suggests the tumor is suppressing local immune activation, allowing it to grow.
Seizures are a common occurrence in childhood brain tumor survivors, affecting 24% at the start and 14% on an ongoing basis. Certain factors such as tumor type and extent of surgery contribute to seizure risk, impacting treatment management.
A study published in Nature found that guppies evolved 135 genes in response to a new environment, with most changes affecting biological processes like metabolism and immune function. However, the initial response was often opposite to the eventual evolutionary change, suggesting that genes can adapt quickly in the short term.
A study published in Neurosurgery found that complete resection of high-grade brain cancer significantly improves survival rates in children. The study revealed a greater survival benefit for female patients compared to male patients. Gross total resection (GTR) improved the chances of survival free of recurrent or progressive cancer o...
Scientists have discovered a cytokine called MIF that regulates EGFR activation in the tumor microenvironment, promoting tumor progression. The findings could lead to new approaches in treating tumors by intervening in this self-regulating loop.
A targeted therapy called vismodegib is effective against the SHH subtype of medulloblastoma in adults, which accounts for about 60% of tumors. The drug blocks a key protein in the sonic hedgehog signaling pathway and has been shown to shrink or disappear tumors in four adult participants.
Researchers have developed a new therapy that slows the spread of deadly brain tumor cells by disrupting their communication pathway. The treatment improved patient survival by 50% in a mouse model and has potential as an adjunct to traditional chemotherapy and radiation treatments.
Erlangen-based doctors have created a new classification system for brain tumors that predicts the development of gliomas with high precision. The Friedlein Grading A/B (FGA/B) system classifies tumors according to their position in the brain on routine MRI scans.
Researchers found that glucose and acetate can activate key tumor signaling molecule mTORC2, allowing tumors to resist targeted therapies like EGFR inhibitors. This discovery provides a potential window into treating glioblastoma, a deadly brain cancer with limited treatment options.
Researchers at Cedars-Sinai Medical Center identified Ets family genes as contributors to glioma brain tumors. Blocking these genes may lead to novel treatment therapies.
Scientists at the University of Leeds discovered a new protein, DOCK4, that triggers blood vessel growth in breast cancer tumors. Withholding this protein slows tumor growth by impeding blood vessel formation.
Researchers found that dasatinib inhibits proteins promoting cancer growth but also suppresses those protecting against it. The study suggests pretesting patient biopsies can help identify patients who may respond to dasatinib and those who should avoid it.
A national cancer study has found that a tumor's DNA, not just tumor stage, is key to determining if a lower-grade malignant brain tumor may rapidly progress to glioblastoma. The findings could lead to earlier and more aggressive treatment for those tumors projected to be on the fast path.
Researchers at Washington University School of Medicine identified a key player in maintaining brain tumor stem cells' ability to survive and replenish themselves. Disrupting this process using protein CDC20 has been shown to reduce tumor growth by up to 95 percent in mice, offering new hope for treating glioblastoma.
A new classification system has been developed to improve the diagnosis and treatment of low- and intermediate-grade gliomas (LGGs), reducing the reliance on subjective tumor appearance. The system uses molecular and genetic analysis to identify three distinct groups of LGGs with varying prognoses, offering a more objective approach.